Drug
Polatuzumab vedotin clinical trials
Also written Polivy, FCU 2711 and RG7596.
- studies test it
- 53
- open now
- 28
- in phase 3
- 6
- first study started
- 2014
Keep track of what changes. Save the polatuzumab vedotin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
53 studies that test it; most in 2021 (11)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 11 |
| 2022 | 3 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 43
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 40
Hoffmann-La Roche (11) · Ruijin Hospital (3) · City of Hope Medical Center (2) · Celgene (2) · Peng Liu (2) · SWOG Cancer Research Network (2) · Weill Medical College of Cornell University (1) · University of Rochester (1)
Often tested with
Tested in the same studies.
Rituximab (20) · Mosunetuzumab (9) · Glofitamab (7) · Zanubrutinib (7) · Cyclophosphamide (5) · Obinutuzumab (5) · Doxorubicin (4) · Lenalidomide (4)
Studies
Open first, then newest update. How each study uses polatuzumab vedotin is read from its arms, and is right about nine times in ten.
Testing it · 53
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingPhase 2Christine RyanNCT06043674Written as Polatuzumab Vedotin
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingPhase 2National Research Center for Hematology, RussiaNCT07883135Written as Polatuzumab Vedotin
- Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingPhase 2Shanghai Zhongshan HospitalNCT07012980Written as Polatuzumab Vedotin
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2SWOG Cancer Research NetworkNCT05633615Written as Polatuzumab Vedotin
- Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07638722Written as Polatuzumab Vedotin
- Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular LymphomaRecruitingPhase 2City of Hope Medical CenterNCT06453044Written as Polatuzumab Vedotin
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingPhase 2Brown UniversityNCT07502872Written as Polatuzumab vedotin
- Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell LymphomaRecruitingPhase 2Medical College of WisconsinNCT06594939Written as Polatuzumab Vedotin
- CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07397832Written as Polatuzumab Vedotin
- The CARDIOPROTECT TrialRecruitingPhase 2Beth Israel Deaconess Medical CenterNCT07654426Written as Polatuzumab Vedotin
- AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCLNot yet recruitingPhase 2Ruijin HospitalNCT07717177Written as Polatuzumab Vedotin
- A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOPNot yet recruitingPhase 2Yonsei UniversityNCT07702851Written as Polatuzumab vedotin, Glofitamab
- Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT06015880Written as Polatuzumab Vedotin
- Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell LymphomaNot yet recruitingPhase 2Ou Bai, MD/PHDNCT07677813Written as Pola-R-miniCHP+O
- Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin LymphomaRecruitingPhase 1/2New York Medical CollegeNCT04491370Written as Polatuzumab vedotin
- Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCLNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07415980Written as Polatuzumab Vedotin
- Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaNot yet recruitingPhase 2Li ZhimingNCT07231250Written as Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone
- Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingPhase 2Ruijin HospitalNCT07122609Written as Polatuzumab Vedotin
- A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1Not yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07034508Written as Polatuzumab Vedotin
- A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell LymphomaRecruitingPhase 2University College, LondonNCT06071871Written as Polatuzumab vedotin
See all 53 studies that test polatuzumab vedotin →
Given in every arm · 23 — polatuzumab vedotin is usual care beside what is tested
- A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLRecruitingPhase 2M.D. Anderson Cancer CenterNCT05615636Written as Polatuzumab vedotin
- A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid MalignanciesRecruitingPhase 1Janssen Research & Development, LLCNCT07308132Written as Polatuzumab vedotin
- Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit PatientsNot yet recruitingPhase 1Jonsson Comprehensive Cancer CenterNCT07714421Written as Polatuzumab Vedotin
- Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07638787Written as Polatuzumab Vedotin
- AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCLNot yet recruitingPhase 2Ruijin HospitalNCT07594899Written as Polatuzumab Vedotin
- Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS LymphomaRecruitingPhase 1Juan P. Alderuccio, MDNCT06730542Written as Polatuzumab Vedotin
- Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLRecruitingPhase 2Ruijin HospitalNCT06803693Written as Polatuzumab vedotin
- Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCLRecruitingPhase 2Affiliated Hospital of Nantong UniversityNCT06530511Written as Polatuzumab vedotin
- Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingPhase 2Ruijin HospitalNCT06441097Written as Polatuzumab vedotin
- Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell LymphomaActive, not recruitingPhase 1/2University of WashingtonNCT04231877Written as Polatuzumab Vedotin
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaActive, not recruitingPhase 3Hoffmann-La RocheNCT06047080Written as Polatuzumab vedotin
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)Active, not recruitingPhase 1ADC Therapeutics S.A.NCT04970901Written as Polatuzumab Vedotin
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingPhase 2GenmabNCT05283720Written as Polatuzumab Vedotin
- Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)Active, not recruitingPhase 1/2Washington University School of MedicineNCT06040320Written as Polatuzumab vedotin
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaActive, not recruitingPhase 1/2University of WashingtonNCT05455697Written as Polatuzumab Vedotin
- Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)WithdrawnPhase 1/2Karyopharm Therapeutics IncNCT04607772Written as Polatuzumab Vedotin
- A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin LymphomaActive, not recruitingPhase 1/2Hoffmann-La RocheNCT03671018Written as Polatuzumab vedotin
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)Active, not recruitingPhase 1/2Peter MacCallum Cancer Centre, AustraliaNCT04914741Written as Polatuzumab vedotin
- A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)CompletedPhase 1/2Hoffmann-La RocheNCT02611323Written as Polatuzumab Vedotin
- A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's LymphomaCompletedPhase 1/2Genentech, Inc.NCT01992653Written as Polatuzumab Vedotin
Showing 20 of 23.
As the comparator · 2 — what is tested is compared with polatuzumab vedotin
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06890884Written as Polatuzumab vedotin
- Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell LymphomaActive, not recruitingPhase 1Mayo ClinicNCT04323956Written as Polatuzumab Vedotin
Codes
What other systems call polatuzumab vedotin · ClinicalTrials.gg INT000299
- MeSH (NLM) C000600736polatuzumab vedotinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) KG6VO684Z6POLATUZUMAB VEDOTINConfirmed FDA, NLM, Wikidata
- RxNorm 2174090One source FDA
- Wikidata Q19946115Polatuzumab vedotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C104153Polatuzumab VedotinOne source FDA
- DrugBank DB12240One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000600736 | polatuzumab vedotin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | KG6VO684Z6 | POLATUZUMAB VEDOTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2174090 | — | One source FDA |
| Wikidata | Q19946115 | Polatuzumab vedotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C104153 | Polatuzumab Vedotin | One source FDA |
| DrugBank | DB12240 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.